base editing

News

Beam launches $500m financing on base-editing trial data

Beam says its base-editing drug has met its goals in a phase 1/2 trial in genetic disease AATD, and it wants to raise $500m to take it forward.

News

Beam Therapeutics' chief executive John Evans

Beam points to positive data with key base editing asset

It has been around a year since Beam Therapeutics slashed its headcount and R&D programmes to focus mainly on a sickle cell disease candidate – and the biotech has now revealed the firs

News

Beam cuts one in five staffers to conserve cash

Gene-editing company Beam Therapeutics has shifted into reverse, slashing staff and R&D programmes after a period of expansion since its public debut in 2020.

Beam launches $500m financing on base-editing trial data

Beam points to positive data with key base editing asset

Beam cuts one in five staffers to conserve cash

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Editor's Picks